# Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis

> **NCT04036721** · PHASE4 · SUSPENDED · sponsor: **National Institute for Tuberculosis and Lung Diseases, Poland** · enrollment: 85 (estimated)

## Conditions studied

- Lung Neoplasm Malignant
- Interstitial Lung Disease

## Interventions

- **DRUG:** Prolonged glucocorticosteroid (prednisone) regimen
- **DRUG:** Short glucocorticosteroid (prednisone) regimen

## Key facts

- **NCT ID:** NCT04036721
- **Lead sponsor:** National Institute for Tuberculosis and Lung Diseases, Poland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-10-01
- **Primary completion:** 2024-02-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 85 (ESTIMATED)
- **Why stopped:** SARS-CoV-2 cases stopped the recruitment in Organisation since July 2020
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036721, "Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04036721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*